Safely, tolerability, and mechanisms of antiretroviral activity of pegylated interferon alfa-2a in HIV-1monoinfected participants: A phase II clinical trial

Journal of Infectious Diseases

Volumn 201, Issue 11, 2010, Pages 1686-1696

  Asmuth, David M ^a   Murphy, Robert L ^c   Rosenkranz, Susan L ^d   Lertora, Juan J L ^e   Kottilil, Shyam ^e   Cramer, Yoninah ^d   Chan, Ellen S ^d   Schooley, Robert T ^b   Rinaldo, Charles R ^g   Thielman, Nathan ^h   Li, Xiao Dong ^g   Wahl, Sharon M ^e   Shore, Jessica ^c   Janik, Jennifer ⁱ   Lempicki, Richard A ^f   Simpson, Yaa ^c   Pollard, Richard B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

^f SAIC FREDERICK INC   (United States)

^g UNIVERSITY OF PITTSBURGH   (United States)

^h DUKE UNIVERSITY   (United States)

ⁱ FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2',5' OLIGOADENYLATE SYNTHETASE; PEGINTERFERON ALPHA2A; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; ALPHA2A INTERFERON; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; MACROGOL DERIVATIVE; PEGINTERFERON ALFA-2A; VIRUS RNA;

ADULT; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG CLEARANCE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ENZYME ACTIVITY; FATIGUE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LEUKOCYTE COUNT; MALE; NEUTROPENIA; NEUTROPHIL COUNT; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTE COUNT; VIRUS LOAD; BLOOD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; GENE EXPRESSION PROFILING; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METABOLISM; MIDDLE AGED; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VIROLOGY;

2',5'-OLIGOADENYLATE SYNTHETASE; ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; GENE EXPRESSION PROFILING; HIV INFECTIONS; HIV-1; HUMANS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 77951889263     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/652420     Document Type: Article

References (41)

1. Biron CA. Role of early cytokines, including alpha and beta interferons (IFN-α/β), in innate and adaptive immune responses to viral infections. Semin Immunol 1998 10(5):383-390.
2. Knop J. Immunologic effects of interferon. J Invest Dermatol 1990 95(suppl 6);72S-74S.
3. Le Bon A, Etchart N, Rossmann C, et al. Cross-priming of CD8 T cells stimulated by virus-induced type 1 interferon. Nat Immunol 2003;4(10):1009-1015. (Pubitemid 37265922)
4. Nokta MA, Reichman RC, Pollard RB. Pathogenesis of viral infections. In; Galasso GJ, Whitley RJ, Merigan TC, eds. Antiviral agents and viral diseases of man. 3rd ed. New York; Raven Press, 1990:49-85.
5. Samuel CE. Antiviral actions of interferons. Clin Microbiol Rev 2001 14(4);778-809.
6. Malmgaard L. Induction and regulation of IFNs during viral infections. J Interferon Cytokine Res 2004;24(8);439-454. (Pubitemid 39120592)
7. Shirazi Y, Pitha PM. Alpha interferon inhibits early stages of the hu- man immunodeficiency virus type 1 replication cycle. J Virol 1992 66(3); 1321-1328.
8. Dianzani F, Castilletti C, Gentile M, Gelderblom HR, Frezza F, Capobianchi MR. Effects of IFNa on late stages of HIV-1 replication cycle. Biochimie 1998;80(8-9);745-754. (Pubitemid 29497592)
9. Peng G, Lei KJ, Jin W, Greenwell-Wild T, Wahl SM. Induction of APOBEC3 family proteins, a defensive maneuver underlying interferon-induced anti-HIV-1 activity. J Exp Med 2006 203(1);41-64.
10. Chen K, Huang J, Zhang C, et al. Alpha interferon potently enhances the anti-human immunodeficiency virus type 1 activity of APOBEC3G in resting primary CD4 T cells. J Virol 2006 80(15);7645-7657.
11. Lempicki RA, Polis MA, Yang J, et al. Gene expression profiles in hepatitis C virus (HCV) and HIV coinfection; class prediction analyses before treatment predict the outcome of anti-HCV therapy among HIV-coinfected persons. J Infect Dis 2006 193(8);1172-1177.
12. Perry CM, Jarvis B. Peginterferon-α-2a (40kD); a review of its use in the management of chronic hepatitis C. Drugs 2001 61(15);2263-2288.
13. Rajender RK, Modi MW, Pedder S. Use of peginterferon alfa-2a (40 KD) (Pegasys) for the treatment of hepatitis C. Adv Drug Deliv Rev 2002 54(4):571-1186
14. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002 347(13);975-982.
15. Chan HL, Leung NW, Hui AY, et al. A randomized, controlled trial of combination therapy for chronic hepatitis B; comparing pegylated interferon-a2b and lamivudine with lamivudine alone. Ann Intern Med 2005 142(4);240-250.
16. Adalid-Peralta L, Godot V, Colin C, et al. Stimulation of the primary anti-HIV antibody response by IFN-a in patients with acute HIV-1 infection. J Leukoc Biol 2008 83(4);1060-1067.
17. Emilié D, Burgard M, Lascoux-Combe C, et al. Early control of HIV replication in primary HIV-1 infection treated with antiretroviral drugs and pegylated IFNα; results from the Primoferon A (ANRS 086) Study. AIDS 2001 15(11);1435-1437.
18. Di Bisceglie AM, Ghalib RH, Hamzeh FM, Rustgi VK. Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C. J Viral Hepat 2007 14(10);721-429.
19. Diago M, Crespo J, Olveira A, et al. Clinical trial; pharmacodynamics and pharmacokinetics of re-treatment with fixed-dose induction of peginterferon α-2a in hepatitis C virus genotype 1 true non-responder patients. Aliment Pharmacol Ther 2007;26(8);1131-1138. (Pubitemid 47480964)
20. Herbeuval JP, Shearer GM. HIV-1 immunopathogenesis; how good interferon turns bad. Clin Immunol 2007 123(2);121-128.
21. Isaacs AJ, Lindenmann JA. Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci 1957 147(927);258-267.
22. Ho DD, Hartshorn KL, Rota TR, et al. Recombinant human interferon alfa-A suppresses HTLV-III replication in vitro. Lancet 1985 1(8429); 602-604.
23. Krown SE, Real FX, Vadhan-Raj S, et al. Kaposi's sarcoma and the acquired immune deficiency syndrome; treatment with recombinant interferon alpha and analysis of prognostic factors. Cancer 1986; 57(suppl 8); 1662-1665. (Pubitemid 16114313)
24. Krown SE, Real FX, Cunningham-Rundles S, et al. Preliminary observations on the effect of recombinant leukocyte A interferon in homosexual men with Kaposi's sarcoma. N Engl J Med 1983 308(18); 1071-1076.
25. Abrams DI, Volberding PA. Alpha interferon therapy of AIDS-associated Kaposi's sarcoma. Semin Oncol 1986 13(3 suppl 2);43-47.
26. Volberding PA, Mitsuyasu R. Recombinant interferon alpha in the treatment of acquired immune deficiency syndrome-related Kaposi's sarcoma. Semin Oncol 1985 12(4 suppl 5);2-6.
27. Lane HC, Kovacs JA, Feinberg J, et al. Anti-retroviral effects of interferon-alpha in AIDS-associated Kaposi's sarcoma. Lancet 1988 2(8622); 1218-1222.
28. de Wit R, Schattenkerk JK, Boucher CA, Bakker PJ, Veenhof KH, Danner SA. Clinical and virological effects of high-dose recombinant interferon-alpha in disseminated AIDS-related Kaposi's sarcoma. Lancet 1988 2(8622);1214-1217.
29. Krown SE, Gold JW, Niedzwiecki D, et al. Interferon-alpha with zidovudine; safety, tolerance, and clinical and virologic effects in patients with Kaposi sarcoma associated with the acquired immunodeficiency syndrome (AIDS) [published correction appears in Ann Intern Med 1990; 113(4);334]. Ann Intern Med 1990 112(11);812-821.
30. Krown SE, Lee JY, Lin L, Fischl MA, Ambinder R, Von Roenn JH. Interferon-a2b with protease inhibitor-based antiretroviral therapy in patients with AIDS-associated Kaposi sarcoma; an AIDS malignancy consortium phase I trial. J Acquir Immune Defic Syndr 2006 41(2); 149-153.
31. Krown SE, Aeppli D, Balfour HH Jr. Phase II, randomized, open-label, community-based trial to compare the safety and activity of combination therapy with recombinant interferon-α2b and zidovudine versus zidovudine alone in patients with asymptomatic to mildly symptomatic HIV infection; HIV Protocol C91-253 Study Team. J Acquir Immune Defic Syndr Hum Retroviral 1999 20(3);245-254.
32. Krown SE, Paredes J, Bundow D, Polsky B, Gold JW, Flomenberg N. Interferon-a, zidovudine, and granulocyte-macrophage colony-stimulating factor; a phase I AIDS Clinical Trials Group study in patients with Kaposi's sarcoma associated with AIDS. J Clin Oncol 1992 10(8); 1344-1351.
33. Mildvan D, Bassiakos Y, Zucker ML, et al. Synergy, activity and tolerability of zidovudine and interferon-alpha in patients with symptomatic HIV-1 infection; AIDS Clincal Trial Group 068. Antivir Ther 1996 1(2);77-88.
34. 6/L; results of the Zidon trial. AIDS 1995 9(9);1025-1035.
35. Skillman DR, Malone JL, Decker CF, et al. Phase I trial of interferon alfa-n3 in early-stage human immunodeficiency virus type 1 disease; evidence for drug safety, tolerance, and antiviral activity. J Infect Dis 1996 173(5);1107-1114.
36. Hatzakis A, Gargalianos P, Kiosses V, et al. Low-dose IFN-α monotherapy in treatment-naive individuals with HIV-1 infection; evidence of potent suppression of viral replication. J Interferon Cytokine Res 2001 21(10);861-869.
37. Torriani FJ, Ribeiro RM, Gilbert TL, et al. Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) dynamics during HCV treatment in HCV/HIV coinfection. J Infect Dis 2003 188(10):1498-1507.
38. Neumann A, Polis M, Rozenberg L, et al. Differential antiviral effect of PEG-interferon-a-2b on HIV and HCV in the treatment of HIV/ HCV co-infected patients. AIDS 2007 21(14);1855-1865.
39. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIVinfected patients. N Engl J Med 2004 351(5);438-450.
40. Zeuzem S, Welsch C, Herrmann E. Pharmacokinetics of peginterferons. Semin Liver Dis 2003 23(suppl 1):23-28.
41. Bruno R, Sacchi P, Ciappina V, et al. Viral dynamics and pharmacokinetics of peginterferon alpha-2a and peginterferon alpha-2b in naive patients with chronic hepatitis c; a randomized, controlled study. Antivir Ther 2004 9(4):491-1197